← Browse by Condition
Medical Condition

liver neoplasms

Total Trials
3
Recruiting Now
3
Trial Phases
Phase 2

ClinicalMetric tracks all active clinical trials for liver neoplasms sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — liver neoplasms Clinical Trials

How many clinical trials are currently recruiting for liver neoplasms?
ClinicalMetric currently tracks 3 actively recruiting clinical trials for liver neoplasms, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 3. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for liver neoplasms?
liver neoplasms research spans Phase 2 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a liver neoplasms clinical trial?
Eligibility criteria for liver neoplasms trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 2
1
Top Sponsors
Shanghai Zhongshan Hospital 1 trial
UMC Utrecht 1 trial
Yonsei University 1 trial

Recruiting Clinical Trials

NCT06794073
Recruiting
Efficacy and Safety of Multimodal Ablation Combined With PD-1 Monoclonal Antibody, Lenvatinib and TACE in the Treatment of Unresectable Primary Hepatocellular Carcinoma: A Single-Arm, Single-Center Clinical Study
Enrollment
17 pts
Location
China
Sponsor
Shanghai Zhongshan Hospital
View Trial →
NCT04075305
Recruiting
The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study
Enrollment
8,000 pts
Location
United States, Austr...
Sponsor
UMC Utrecht
View Trial →
NCT07246668 Phase 2
Recruiting
A Phase II Single-Arm Clinical Study to Evaluate the Efficacy and Safety of Carbon Ion Radiotherapy With Atezolizumab and Bevacizumab Combination Therapy in Patients With Advanced Hepatocellular Carcinoma
Enrollment
52 pts
Location
South Korea
Sponsor
Yonsei University
View Trial →

Related Conditions

carcinoma hepatocellular (1) neoplasms glandular and epithelial (1) adenocarcinoma (1) digestive system neoplasms (1) oncology (1) breast cancer (1) prostate cancer (1) gynecologic cancer (1) brain tumor (1) brain cancer (1) gynecologic tumor (1) prostate tumor (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: November 2026  ·  Data Methodology